Firm allegedly touted stocks on social media, while selling its holdings
Exec misled investors by inflating target's revenues to enable SPAC deal
Long-running scheme misled investors on stock markups, fees
Court orders prison, restitution for misappropriating investors' money
Company, executives agree to settle allegations, pay US$41 million
Increase in claimed class-action damages points to larger settlements
Execs falsely inflated firm's revenues to enable acquisition, regulator charges
Ex-CEO misled investors over regulatory approval for new drugs
U.S. authorities allege biostatistician traded on cancer drug data
Regulator settled with Rio Tinto, former CEO in 2023